GlassScriptPhysician profile
Sandeep S Mann
NPI 1891776761
$6,089.26
in general payments reported to CMS, 2019-2025
44 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $710 · 2021: $871 · 2022: $600 · 2023: $631 · 2024: $942 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.42 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $915.62 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Pfizer INC. | $780.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $533.15 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $446.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $401.03 | 2019-2025 | Veozah |
| Amgen INC. | $383.13 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $328.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $199.36 | 2019-2022 | |
| Dexcom, INC. | $160.89 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.57 | 2019-2025 | Jardiance |
| Abbott Laboratories | $152.38 | 2021-2025 | Jot Dx, Freestyle Libre 3, Assurity |
| Novartis Pharmaceuticals Corporation | $146.30 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $136.74 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $130.48 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $119.55 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.